Rexahn Pharmaceuticals Inc.

Stock Update (NYSE MKT:RNN): Rexahn Pharmaceuticals, Inc. Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma

Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it has identified …

Corey Williams — February 8, 2016, 9:44 AM EDT

Company Update (NYSE MKT:RNN): Rexahn Pharmaceuticals, Inc. Announces Supinoxin™ Poster Presentations at the 2016 Gastrointestinal Cancers Symposium

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that the Company presented …

Corey Williams — January 25, 2016, 9:18 AM EDT

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc.’s New Preclinical Data for Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new …

Corey Williams — January 12, 2016, 9:32 AM EDT

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc.’s Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced additional interim clinical data from …

Corey Williams — January 11, 2016, 9:27 AM EDT

Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals Inc. Announces New Data for Supinoxin™ Showing Potent Tumor Growth Inhibition

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new …

Corey Williams — December 14, 2015, 9:23 AM EDT

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Announces $7.0 Million Registered Direct Offering

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has entered into a definitive agreement with a single institutional investor to purchase approximately 16.

Corey Williams — November 6, 2015, 9:13 AM EDT

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium

Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that interim clinical data …

Corey Williams — November 5, 2015, 9:54 AM EDT

Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results and Provides Corporate Update

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the third …

Corey Williams — November 3, 2015, 9:14 AM EDT

Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Receives U.S. Patent for RX-3117 Anti-Cancer Program

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it has been issued …

Corey Williams — October 26, 2015, 9:43 AM EDT

Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that preliminary clinical data …

Corey Williams — September 28, 2015, 9:13 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts